스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

orifarm ab - amfotericin b - pulver till infusionsvätska, lösning - 50 mg - sackaros hjälpämne; amfotericin b 50 mg aktiv substans - amfotericin b

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

omnia läkemedel ab - amfotericin b - pulver till infusionsvätska, lösning - 50 mg - sackaros hjälpämne; amfotericin b 50 mg aktiv substans

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

orifarm ab - amfotericin b - pulver till infusionsvätska, lösning - 50 mg - amfotericin b 50 mg aktiv substans; sackaros hjälpämne

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

abacus medicine a/s - amfotericin b - pulver till infusionsvätska, dispersion - 50 mg - amfotericin b 50 mg aktiv substans; sackaros hjälpämne

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

abacus medicine a/s - amfotericin b - pulver till infusionsvätska, dispersion - 50 mg - amfotericin b 50 mg aktiv substans; sackaros hjälpämne

유럽 연합 - 스웨덴어 - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiska medel - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

유럽 연합 - 스웨덴어 - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfom, mantelcell - antineoplastiska medel - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).